PIP is a tool developed by MIA to ensure advanced melanoma patients receive effective treatment the first time, based on their own genetics and tumour biology.
The ABC-X clinical trial seeks to determine if the addition of radiotherapy, to combination immunotherapy, results in improved outcomes for patients with melanoma brain metastases.
Developing a screening technique to provide clinicians with rationale for selecting a drug treatment regime.
Understanding the genes involved in the development of early brain metastases.
Identifying genes involved in all melanoma sub-types, to determine the most effective treatment.
Using whole genome sequencing technologies to identify the genetic mutations that cause melanoma, so treatment can be personalised.
Identifying genes which determine response to immunotherapy, and then determining the signalling pathways these genes are affecting.
MIA is experiencing great success with multi-discipline trials in the neo-adjuvant and adjuvant settings.
Research to determine the value of providing patients with the services of a support clinic following dissection surgery.
An observational study to determine best practice based on clinicians’ reported management of NSW melanoma patients over a 12-month period.